| 1 |
2021 |
Genetics of frontotemporal dementia in China. |
ACMG, ALS, FTD, FTLD-TDP, VUS |
| 2 |
2020 |
Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing. |
snRNP |
| 3 |
2020 |
Disease-Associated Mutant Tau Prevents Circadian Changes in the Cytoskeleton of Central Pacemaker Neurons. |
AD, EB1, hTau |
| 4 |
2020 |
Dysregulation of Exosome Cargo by Mutant Tau Expressed in Human-induced Pluripotent Stem Cell (iPSC) Neurons Revealed by Proteomics Analyses. |
AD, iPSC, mTau, p-Tau |
| 5 |
2020 |
Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. |
AD, CBD, EOFAD, PSP |
| 6 |
2019 |
A Disease-Causing Intronic Point Mutation C19G Alters Tau Exon 10 Splicing via RNA Secondary Structure Rearrangement. |
--- |
| 7 |
2019 |
Amyloid-beta pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo. |
AD, WT |
| 8 |
2019 |
Clinical and Genetic Study of the First Japanese FTDP-17 Patient with a Mutation of +3 in Intron 10 in the MAPT Gene. |
--- |
| 9 |
2019 |
MAPT mutations, tauopathy, and mechanisms of neurodegeneration. |
AD |
| 10 |
2019 |
Reduced expression of dMyc mitigates TauV337M mediated neurotoxicity by preventing the Tau hyperphosphorylation and inducing autophagy in Drosophila. |
AD, NFTs, PiD |
| 11 |
2018 |
Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies. |
--- |
| 12 |
2018 |
Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. |
--- |
| 13 |
2018 |
FTDP-17 Mutations Alter the Aggregation and Microtubule Stabilization Propensity of Tau in an Isoform-Specific Fashion. |
--- |
| 14 |
2018 |
Longitudinal evaluation of Tau-P301L transgenic mice reveals no cognitive impairments at 17months of age. |
5-CSRTT, AD, FTD, OR |
| 15 |
2018 |
Sleep Architecture Changed Without RBD in Patients With FTDP-17. |
PD, PSG |
| 16 |
2017 |
11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset. |
MAPT |
| 17 |
2017 |
A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo. |
--- |
| 18 |
2017 |
Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. |
MAPT |
| 19 |
2017 |
Increased 4R tau expression and behavioural changes in a novel MAPT-N296H genomic mouse model of tauopathy. |
PAC |
| 20 |
2017 |
Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads to oxidative stress and neurodegeneration. |
--- |
| 21 |
2016 |
Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models. |
AD, MAPT |
| 22 |
2016 |
Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. |
GGT, MAPT |
| 23 |
2016 |
FTDP-17 with Pick body-like inclusions associated with a novel tau mutation, p.E372G. |
bvFTD, MAPT |
| 24 |
2016 |
Generation of an isogenic, gene-corrected iPSC line from a pre-symptomatic 28-year-old woman with an R406W mutation in the microtubule associated protein tau (MAPT) gene. |
iPSCs, MAPT |
| 25 |
2016 |
Generation of an isogenic, gene-corrected iPSC line from a symptomatic 57-year-old female patient with frontotemporal dementia caused by a P301L mutation in the microtubule associated protein tau (MAPT) gene. |
iPSCs, MAPT |
| 26 |
2016 |
Generation of an isogenic, gene-corrected iPSC line from a symptomatic 59-year-old female patient with frontotemporal dementia caused by an R406W mutation in the microtubule associated protein tau (MAPT) gene. |
iPSCs, MAPT |
| 27 |
2016 |
In Vivo Imaging of Tau Aggregates in the Mouse Retina. |
--- |
| 28 |
2016 |
Induced pluripotent stem cells (iPSCs) derived from a symptomatic carrier of a S305I mutation in the microtubule-associated protein tau (MAPT)-gene causing frontotemporal dementia. |
iPSCs, MAPT |
| 29 |
2016 |
MAPT mutation associated with frontotemporal dementia and parkinsonism (FTDP-17). |
--- |
| 30 |
2016 |
Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo. |
AD |
| 31 |
2016 |
Quantitative and combinatory determination of in situ phosphorylation of tau and its FTDP-17 mutants. |
--- |
| 32 |
2016 |
Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation. |
AD, dMyc |
| 33 |
2015 |
Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. |
CSF, NFTs |
| 34 |
2015 |
Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. |
iPSCs, NSCs, PPND |
| 35 |
2015 |
Homozygous MAPT R406W mutation causing FTDP phenotype: A unique instance of a unique mutation. |
--- |
| 36 |
2015 |
Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity. |
AD |
| 37 |
2015 |
Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons. |
AD, GSK-3beta, LOV, NMDA, OA, PP2A |
| 38 |
2015 |
Structural determinants for alternative splicing regulation of the MAPT pre-mRNA. |
SRE, WT |
| 39 |
2015 |
Systematic review and meta-analysis of Japanese familial Alzheimer's disease and FTDP-17. |
FAD |
| 40 |
2014 |
Bottom-up design of small molecules that stimulate exon 10 skipping in mutant MAPT pre-mRNA. |
MAPT |
| 41 |
2014 |
Cathepsin D in a murine model of frontotemporal dementia with Parkinsonism-linked to chromosome 17. |
AD |
| 42 |
2014 |
Frontotemporal dementia with parkinsonism linked to chromosome 17 with the MAPT R406W mutation presenting with a broad distribution of abundant senile plaques. |
Abeta42, AD, CERAD, MAPT |
| 43 |
2014 |
Huntington's disease is a four-repeat tauopathy with tau nuclear rods. |
HD |
| 44 |
2014 |
Phosphatases of alpha-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. |
MAPT, PD |
| 45 |
2014 |
Physiological and pathological phosphorylation of tau by Cdk5. |
AD, CDKs |
| 46 |
2014 |
Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. |
--- |
| 47 |
2014 |
Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. |
AD |
| 48 |
2014 |
The influence of the DeltaK280 mutation and N- or C-terminal extensions on the structure, dynamics, and fibril morphology of the tau R2 repeat. |
--- |
| 49 |
2013 |
Acetylated tau neuropathology in sporadic and hereditary tauopathies. |
AD, AGD, FAD, TPSD |
| 50 |
2013 |
Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. |
PTZ |
| 51 |
2013 |
Interactions between Abeta and mutated Tau lead to polymorphism and induce aggregation of Abeta-mutated tau oligomeric complexes. |
--- |
| 52 |
2013 |
Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites. |
--- |
| 53 |
2013 |
Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain. |
LVs, NFD, WT |
| 54 |
2013 |
Neurodegenerative disorder FTDP-17-related tau intron 10 +16C → T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice. |
--- |
| 55 |
2013 |
Ubiquilin 2 is not associated with tau pathology. |
AD, ALS, PiD |
| 56 |
2012 |
A new link to mitochondrial impairment in tauopathies. |
WT |
| 57 |
2012 |
Agraphia in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 with P301L MAPT mutation: dysexecutive, aphasic, apraxic or spatial phenomenon? |
--- |
| 58 |
2012 |
Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer's disease and FTDP-17. |
AD |
| 59 |
2012 |
Hrd1 facilitates tau degradation and promotes neuron survival. |
AD, p-tau |
| 60 |
2011 |
Evidence for a Common Founder and Clinical Characteristics of Japanese Families with the MAPT R406W Mutation. |
SNPs |
| 61 |
2011 |
Identification of ligands for the Tau exon 10 splicing regulatory element RNA by using dynamic combinatorial chemistry. |
CD, DCC |
| 62 |
2011 |
Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy. |
DA, DAr |
| 63 |
2011 |
NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. |
NAD |
| 64 |
2011 |
T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice. |
AD |
| 65 |
2011 |
The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. |
AD, ANXA2 |
| 66 |
2011 |
The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. |
AD, ER, FTLD-tau, p-IRE1, p-tau, PiD, pPERK, PSP, UPR |
| 67 |
2011 |
Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies. |
AD, FTDP-17T, NFTs, PiD, PSP, TG1, TG2, TGs, TIG3 |
| 68 |
2010 |
Acetylation of tau inhibits its degradation and contributes to tauopathy. |
AD, p-tau |
| 69 |
2010 |
Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. |
--- |
| 70 |
2010 |
Disentangling the role of the tau gene locus in sporadic tauopathies. |
CBD, PD, PSP |
| 71 |
2010 |
Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains. |
AD, MAP |
| 72 |
2010 |
Frontotemporal dementia and parkinsonism linked to chromosome 17--the first Polish family. |
MAPT |
| 73 |
2010 |
In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. |
AChE, HV, PET, PGCs |
| 74 |
2010 |
Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau. |
PSA, si |
| 75 |
2010 |
SJLB mice develop tauopathy-induced parkinsonism. |
--- |
| 76 |
2009 |
Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. |
PSP |
| 77 |
2009 |
Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing. |
PTM, SMaRT |
| 78 |
2009 |
Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau. |
--- |
| 79 |
2009 |
Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. |
AD, PHFs |
| 80 |
2009 |
Intrafamilial clinical phenotypic heterogeneity with MAPT gene splice site IVS10+16C>T mutation. |
MAPT |
| 81 |
2009 |
Transgenic Drosophila models of Alzheimer's disease and tauopathies. |
Abeta42, AD |
| 82 |
2009 |
[Clinical, pathological, and genetic characteristics of frontotemporal dementia and parkinsonism linked to chromosome 17 with mutations in the MAPT and PGRN]. |
MAPT, MAPT, PGRN |
| 83 |
2009 |
[Neurodegeneration and inflammation: analysis of a FTDP-17 model mouse]. |
ACh, AD, DZ, TP |
| 84 |
2009 |
[The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)]. |
AD, FTD |
| 85 |
2008 |
Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. |
AD |
| 86 |
2008 |
In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. |
MAPT, PGRN |
| 87 |
2008 |
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. |
AD |
| 88 |
2008 |
Tau exon 10 alternative splicing and tauopathies. |
--- |
| 89 |
2008 |
Tau-based treatment strategies in neurodegenerative diseases. |
CBD, PiD, PSP |
| 90 |
2007 |
CHIP-ping away at tau. |
AD, CHIP, p-tau |
| 91 |
2007 |
Clinical and genetic features of families with frontotemporal dementia and parkinsonism linked to chromosome 17 with a P301S tau mutation. |
--- |
| 92 |
2007 |
Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). |
PPND |
| 93 |
2007 |
Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. |
--- |
| 94 |
2007 |
Familial early-onset dementia with tau intron 10 + 16 mutation with clinical features similar to those of Alzheimer disease. |
--- |
| 95 |
2007 |
Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. |
--- |
| 96 |
2007 |
Frontotemporal dementia and Parkinsonism linked to chromosome 17 with the N279K tau mutation. |
PPND |
| 97 |
2007 |
Frontotemporal dementia with tau pathology. |
--- |
| 98 |
2007 |
Frontotemporal lobar degeneration: current concepts in the light of recent advances. |
ALS, DLDH, FTLD, FTLD-U, TDP-43 |
| 99 |
2007 |
Hereditary frontotemporal dementia caused by Tau gene mutations. |
--- |
| 100 |
2007 |
Interaction of tau protein with the dynactin complex. |
--- |
A Search Service for Abbreviation / Long Form
